Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Dare Bioscience, Inc. (DARE) reports that Lind Global Fund III LP, its general partner Lind Global Partners III LLC, and the LLC’s managing member Jeff Easton each report beneficial ownership of 1,033,035 shares, or 4.99% of the class, for the September 30, 2026 event date. The fund’s reported ownership consists of Series A and Series B warrants. Their conversion limitations prevent conversion that would cause the holder to beneficially own more than 4.99% of the company.
Key Figures
Beneficial ownership reported:1,033,035 sharesClass ownership percentage:4.99%Series A Warrants:1,094,890 warrants+1 more
4 metrics
Beneficial ownership reported1,033,035 sharesEach reporting person reports this amount for the September 30, 2026 event date.
Class ownership percentage4.99%Reported by each reporting person.
Series A Warrants1,094,890 warrantsWarrants to purchase common stock.
Series B Warrants1,094,890 warrantsWarrants to purchase common stock.
Key Terms
beneficial ownership, Series A Warrants, Series B Warrants, conversion limitations
4 terms
beneficial ownershipfinancial
"beneficial ownership has been limited to 1,033,035 shares in the aggregate"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Series A Warrantsfinancial
"1,094,890 warrants to purchase shares of common stock (the "Series A Warrants")"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
Series B Warrantsfinancial
"1,094,890 warrants to purchase shares of common stock (the "Series B Warrants")"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
conversion limitationstechnical
"due to the conversion limitations on the Warrants"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many DARE shares do the reporting persons report owning?
Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton each report beneficial ownership of 1,033,035 shares, equal to 4.99% of the class, for the September 30, 2026 event date. The LLC is the fund’s general partner, and Easton is the LLC’s managing member.
How many DARE Series A and Series B warrants are reported?
The reported ownership consists of 1,094,890 Series A Warrants and 1,094,890 Series B Warrants, each to purchase common stock. Conversion limitations cap the reported beneficial ownership at 1,033,035 shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Dare Bioscience, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
23666P200
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
23666P200
1
Names of Reporting Persons
Lind Global Fund III LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,033,035.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,033,035.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,033,035.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.99 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 warrants to purchase shares of common stock (the "Series A Warrants") and (ii) 1,094,890 warrants to purchase shares of common stock (the "Series B Warrants," together with the Series A Warrants, the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,033,035 shares in the aggregate.
(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.
SCHEDULE 13G
CUSIP Number(s):
23666P200
1
Names of Reporting Persons
Lind Global Partners III LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,033,035.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,033,035.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,033,035.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 Series A Warrants and (ii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,033,035 shares in the aggregate.
(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.
SCHEDULE 13G
CUSIP Number(s):
23666P200
1
Names of Reporting Persons
EASTON JEFF
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,033,035.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,033,035.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,033,035.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.99 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 1,094,890 Series A Warrants and (ii) 1,094,890 Series B Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 1,033,035 shares in the aggregate.
(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Dare Bioscience, Inc.
(b)
Address of issuer's principal executive offices:
3655 Nobel Drive, Suite 260, San Diego, California, 92122
Item 2.
(a)
Name of person filing:
This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"):
Lind Global Fund III LP, a Delaware limited partnership;
Lind Global Partners III LLC, a Delaware limited liability company; and
Jeff Easton, an individual and a citizen of the United States of America.
Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office for each of the Reporting Persons is:
444 Madison Ave, Floor 41
New York, NY 10022
(c)
Citizenship:
See Row 4 of cover page for each Reporting Person.
(d)
Title of class of securities:
Common Stock, $0.0001 par value
(e)
CUSIP No.:
23666P200
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See Row 9 of cover page for each Reporting Person.
(b)
Percent of class:
See Row 11 of cover page for each Reporting Person.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Row 5 of cover page for each Reporting Person.
(ii) Shared power to vote or to direct the vote:
See Row 6 of cover page for each Reporting Person.
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of cover page for each Reporting Person.
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for each Reporting Person.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.